Summary AC Immune SA (AC Immune) is a biopharmaceutical company that discovers, designs, and develops products for modifying and preventing diseases caused due to misfolded proteins. The company’s pipeline product candidates include anti- abeta antibody, anti-abeta vaccine, anti-ptau vaccine, and tau inhibitor, among others. Its therapeutic and diagnostic candidates are used in the treatment of Alzheimer's disease, Parkinson's disease, glaucoma and down syndrome. AC Immune uses its proprietary technology platforms for generating small molecules, vaccines, and antibodies to address a wide spectrum of neurodegenerative indications. The company partners with pharmaceutical companies and research institutes for advancing the development of its pre-clinical and clinical pipeline products. AC Immune is headquartered in Lausanne, Switzerland. AC Immune SA (ACIU) - Medical Equipment - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed... Research Beam Model: Research Beam Product ID: 1725265 250 USD New
AC Immune SA (ACIU) - Medical Equipment - Deals and Alliances Profile
 
 

AC Immune SA (ACIU) - Medical Equipment - Deals and Alliances Profile

  • Category : Medical Devices
  • Published On : July   2017
  • Pages : 24
  • Publisher : GlobalData
 
 
 
Summary

AC Immune SA (AC Immune) is a biopharmaceutical company that discovers, designs, and develops products for modifying and preventing diseases caused due to misfolded proteins. The company’s pipeline product candidates include anti- abeta antibody, anti-abeta vaccine, anti-ptau vaccine, and tau inhibitor, among others. Its therapeutic and diagnostic candidates are used in the treatment of Alzheimer's disease, Parkinson's disease, glaucoma and down syndrome. AC Immune uses its proprietary technology platforms for generating small molecules, vaccines, and antibodies to address a wide spectrum of neurodegenerative indications. The company partners with pharmaceutical companies and research institutes for advancing the development of its pre-clinical and clinical pipeline products. AC Immune is headquartered in Lausanne, Switzerland.

AC Immune SA (ACIU) - Medical Equipment - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
AC Immune SA, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
AC Immune SA, Medical Equipment Deals By Type, 2011 to YTD 2017 6
AC Immune SA, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
AC Immune SA, Medical Equipment, Deals By Market, 2011 to YTD 2017 8
AC Immune SA, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
AC Immune SA, Medical Equipment, Deal Details 10
Partnerships 10
Nestle Institute of Health Sciences Enters into Research Agreement with AC Immune 10
AC Immune Enters into Research Agreement with Nestle Institute of Health Sciences 10
AC Immune Enters Into License Agreement With Piramal Imaging 11
Equity Offering 12
AC Immune Prices IPO for USD66 Million 12
AC Immune SA - Key Competitors 14
Key Employees 15
Locations And Subsidiaries 16
Head Office 16
Recent Developments 17
Financial Announcements 17
May 11, 2017: AC Immune Reports First Quarter 2017 Financial Results 17
Mar 17, 2017: AC Immune Reports Full Year 2016 Financial Results and R&D Update 19
Nov 11, 2016: AC Immune Reports Third Quarter 2016 Results 22
Corporate Communications 23
Nov 23, 2016: AC Immune Appoints Experienced Life Science Professional As New Chief Financial Officer 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24
List of Tables
AC Immune SA, Medical Equipment, Key Facts, 2016 1
AC Immune SA, Medical Equipment, Deals Summary, 2011 to YTD 2017 1
AC Immune SA, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
AC Immune SA, Medical Equipment Deals By Type, 2011 to YTD 2017 6
AC Immune SA, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
AC Immune SA, Deals By Market, 2011 to YTD 2017 8
AC Immune SA, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
Nestle Institute of Health Sciences Enters into Research Agreement with AC Immune 10
AC Immune Enters into Research Agreement with Nestle Institute of Health Sciences 10
AC Immune Enters Into License Agreement With Piramal Imaging 11
AC Immune Prices IPO for USD66 Million 12
AC Immune SA, Key Competitors 14
AC Immune SA, Key Employees 15
PURCHASE OPTIONS
 
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter